Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
US9708596B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 1, 2015 |
| Grant date | Jul 18, 2017 |
| Priority date | — |
| Expiry date | Dec 1, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y406/01001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. The mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermore have a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.